RxDoctor Payments Data

Chima Asikaiwe, MD

Psychiatry · Dallas, TXNPI 1992003669

Payments from drug & device makers

$1,821in general payments, 2019–2025

Across 101 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$662
  • Johnson & Johnson$197
  • Corium, LLC$193
  • Supernus Pharmaceuticals, Inc.$135
  • Brainsway USA Inc$118
  • Vanda Pharmaceuticals Inc.$117
  • plus $398 from 9 others

What the payments were for

  • Food & beverage$1,821100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,821 in reported general payments places this provider in the 75th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$392,196
Medicare patients
958
Services billed
3,235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuedextaDextromethorphan Hbr/Quinidine23$18,061
Invega SustennaPaliperidone Palmitate14$16,358
Aripiprazole104$7,346
Oxcarbazepine103$3,521
Desvenlafaxine Succinate ErDesvenlafaxine Succinate47$2,607
Buspirone Hcl191$2,215
Atomoxetine Hcl27$1,649
Divalproex Sodium92$1,583
Gabapentin112$1,553
Mirtazapine86$1,454
Quetiapine Fumarate41$1,319
Bupropion XlBupropion Hcl102$1,271
Duloxetine Hcl40$1,261
Trazodone Hcl111$1,084
Hydroxyzine Pamoate98$900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$197$16,35814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →